Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • US Politics
    US Politics
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

Article Tools/Herramientas de artículos

+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña




Globe NewsWire News Distribution Service


紐約, Feb. 15, 2025 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 提醒在 2024 年 1 月 19 日至 2024 年 9 月 19 日(包括首尾兩日,簡稱「集體訴訟期」)期間購買了股份公司 Kaspi.kz (NASDAQ: KSPI) 證券之人士注意,在該事務所首次提出的證券集體訴訟中,重要的首席原告截止日期為 2025 年 2 月 18 日。


Posted: 2025-02-15 06:09:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From Current Category Plus Bonus Features From The Web

Press Release: Best Delta 8 Gummies of 2025: Area 52 Named #1 Edible by Oregon Observer

Mon, 07 Jul 2025 04:07:52 +0000

Las Vegas, NV, July 06, 2025 (GLOBE NEWSWIRE) -- In a landmark achievement that solidifies Area 52's position as the Delta 8 market leader, The Oregon Observer's extensive 2025 cannabis edibles review has awarded the top Delta 8 gummy rankings to Area 52's innovative product line. This unprecedented sweep demonstrates the brand's unwavering commitment to…

Read More ...


Press Release: Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Mon, 07 Jul 2025 01:07:50 +0000

SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EGT Synbio, headquartered in Shanghai, China, has successfully completed two human clinical trials evaluating the effects of oral L-ergothioneine (Dr.Ergo®) on skin health. Abinopharm, Inc. is the…

Read More ...


Press Release: Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Sun, 06 Jul 2025 22:07:52 +0000

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD)…

Read More ...


Press Release: BJMINING Unleashes AI-Powered Energy Arbitrage to Revolutionize Bitcoin Mining Profitability

Sun, 06 Jul 2025 19:07:52 +0000

London, July 06, 2025 (GLOBE NEWSWIRE) -- With Bitcoin currently trading at $107,000 — up 60% year-to-date—many U.S.-based mining operations are facing existential threats as single-coin production costs soar to $137,000. In stark contrast, BJMINING, the UK-based cloud mining giant founded in 2015, has reduced its breakeven threshold to $68,000 by leveraging AI-powered dynamic energy…

Read More ...


Press Release: Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Sun, 06 Jul 2025 16:07:53 +0000

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Read More ...

















Blow Us A Whistle




Related Product Search/Búsqueda de productos relacionados